CA3012791C - Use of gabaa receptor modulators for treatment of itch - Google Patents

Use of gabaa receptor modulators for treatment of itch Download PDF

Info

Publication number
CA3012791C
CA3012791C CA3012791A CA3012791A CA3012791C CA 3012791 C CA3012791 C CA 3012791C CA 3012791 A CA3012791 A CA 3012791A CA 3012791 A CA3012791 A CA 3012791A CA 3012791 C CA3012791 C CA 3012791C
Authority
CA
Canada
Prior art keywords
unsubstituted
substituted
compound
itch
pharmaceutical composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA3012791A
Other languages
English (en)
French (fr)
Other versions
CA3012791A1 (en
Inventor
Hanns Ulrich Zeilhofer
William RALVENIUS
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zurich Universität
Original Assignee
Zurich Universität
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zurich Universität filed Critical Zurich Universität
Priority to CA3222584A priority Critical patent/CA3222584A1/en
Publication of CA3012791A1 publication Critical patent/CA3012791A1/en
Application granted granted Critical
Publication of CA3012791C publication Critical patent/CA3012791C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
CA3012791A 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch Active CA3012791C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA3222584A CA3222584A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP16153035 2016-01-27
EP16153035.7 2016-01-27
EP16178824 2016-07-11
EP16178824.5 2016-07-11
PCT/EP2017/051866 WO2017129801A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA3222584A Division CA3222584A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Publications (2)

Publication Number Publication Date
CA3012791A1 CA3012791A1 (en) 2017-08-03
CA3012791C true CA3012791C (en) 2024-01-23

Family

ID=57890845

Family Applications (2)

Application Number Title Priority Date Filing Date
CA3012791A Active CA3012791C (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch
CA3222584A Pending CA3222584A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA3222584A Pending CA3222584A1 (en) 2016-01-27 2017-01-27 Use of gabaa receptor modulators for treatment of itch

Country Status (14)

Country Link
US (3) US10786513B2 (enExample)
EP (1) EP3407886A1 (enExample)
JP (2) JP7115746B2 (enExample)
KR (1) KR102482200B1 (enExample)
CN (1) CN108697694B (enExample)
AU (1) AU2017213154B2 (enExample)
BR (1) BR112018015386A2 (enExample)
CA (2) CA3012791C (enExample)
CL (1) CL2018002023A1 (enExample)
IL (1) IL260775B (enExample)
MX (1) MX388862B (enExample)
SG (1) SG11201806393QA (enExample)
UA (1) UA125463C2 (enExample)
WO (1) WO2017129801A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112018015386A2 (pt) 2016-01-27 2019-03-19 Universität Zürich uso de moduladores de receptor gabaa para tratamento de prurido
CN112384513A (zh) 2018-04-18 2021-02-19 纽罗塞克医疗公司 Gabaa正变构调节剂化合物、其制备方法和用途
WO2019226820A1 (en) * 2018-05-22 2019-11-28 Neurocycle Therapeutics, Inc. Gabaa positive allosteric modulator compounds for treatment of itch and/ or dermatitis
HUE060943T2 (hu) * 2018-09-13 2023-04-28 Saniona As A gaba A receptor ligandum
WO2020191047A1 (en) * 2019-03-18 2020-09-24 Neurocycle Therapeutics, Inc. Use of gabaa receptor modulators for treatment of pain
CN110004118B (zh) * 2019-03-29 2023-03-28 中国科学院武汉物理与数学研究所 用于辅助重组狂犬病毒在神经细胞高效逆向跨单级突触的rAAV病毒的包装方法及其应用
CA3155618A1 (en) * 2019-10-23 2021-04-29 Jed Hubbs Treatment of epileptic conditions with gabaa receptor modulators
US12233070B2 (en) * 2020-06-30 2025-02-25 University Of Mississippi Medical Center Methods for treating benzodiazepine misuse/use disorder

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1024526A (en) 1911-07-25 1912-04-30 George R Schweikert Chair.
EP0915875B1 (en) * 1996-07-25 2003-04-09 MERCK SHARP & DOHME LTD. Substituted triazolo-pyridazine derivatives as ligands for gaba receptors
FR2767692B1 (fr) * 1997-09-01 2000-03-03 Oreal Utilisation d'une substance agoniste d'un recepteur associe a un canal chlore ou potassique dans le traitement des peaux sensibles
GB9813576D0 (en) 1998-06-24 1998-08-19 Merck Sharp & Dohme Therapeutic agents
GB9903119D0 (en) * 1999-02-11 1999-04-07 Merck Sharp & Dohme Therapeutic agents
AU1253002A (en) 2000-11-10 2002-05-21 Merck Sharp & Dohme Imidazo-triazine derivatives as ligands for gaba receptors
GB0117277D0 (en) 2001-07-16 2001-09-05 Merck Sharp & Dohme Therapeutic agents
TWI248936B (en) 2001-03-21 2006-02-11 Merck Sharp & Dohme Imidazo-pyrimidine derivatives as ligands for GABA receptors
WO2003082832A2 (en) 2002-03-28 2003-10-09 Wisys Technology Foundation, Inc. Anxiolytic agents with reduced sedative and ataxic effects
US8835424B2 (en) 2002-03-28 2014-09-16 Wisconsin Alumni Research Foundation Selective agents for pain suppression
GB0210124D0 (en) 2002-05-02 2002-06-12 Merck Sharp & Dohme Therapeutic agents
JP2004170323A (ja) * 2002-11-22 2004-06-17 Sumitomo Pharmaceut Co Ltd 皮膚疾患治療剤のスクリーニング方法
WO2005030773A1 (ja) * 2003-09-26 2005-04-07 Dainippon Sumitomo Pharma Co., Ltd. 新規ピラゾロピリミジン誘導体
WO2005108401A1 (en) * 2004-04-29 2005-11-17 Dov Pharmaceutical, Inc. 2-pyridinyl[7-(substituted-pyridin-4-yl) pyrazolo[1,5-a]pyrimidin-3-yl]methanones
WO2006061428A2 (en) * 2004-12-10 2006-06-15 Universität Zürich Gaba-a alpha 2 and alpha 3 receptor agonists for treating neuropathic, inflammatory and migraine associated pain
KR20060087386A (ko) * 2005-01-28 2006-08-02 주식회사 대웅제약 신규 벤조이미다졸 유도체 및 이를 함유하는 약제학적조성물
TW200823215A (en) 2006-08-04 2008-06-01 Merz Pharma Gmbh & Amp Co Kgaa Pyrazolopyrimidines, a process for their preparation and the use as a medicine
GEP20125658B (en) 2006-11-22 2012-10-10 Incyte Corp Imidazotriazines and imidazo pyrimidines as kinase inhibitors
WO2009021957A2 (en) * 2007-08-14 2009-02-19 Novartis Ag Tricyclic heterocyclic compounds as gaba a modulators
SI2300455T1 (sl) 2008-05-21 2017-12-29 Incyte Holdings Corporation Soli 2-fluoro-n-metil-4-(7-(kinolin-6-il-metil)-imidazo(1,2-b)1,2,4) triazin-2-il)benzamid in postopki v zvezi z njihovo pripravo
WO2010063487A1 (en) 2008-12-05 2010-06-10 Merz Pharma Gmbh & Co. Kgaa Pyrazolopyrimidines, a process for their preparation and their use as medicine
AU2010239188B2 (en) 2009-04-22 2016-03-31 Janssen Pharmaceutica Nv Azetidinyl diamides as monoacylglycerol lipase inhibitors
EP2456311A4 (en) 2009-07-24 2013-01-23 Concert Pharmaceuticals Inc SUBSTITUTED IMIDASOTRIAZINES
US8809541B2 (en) 2010-08-25 2014-08-19 Neopharm Co., Ltd. Heterocyclic compound, and composition for treating inflammatory diseases using same
US20130331394A1 (en) * 2012-06-11 2013-12-12 The Mclean Hospital Corporation Treating schizophrenia
MX362181B (es) * 2013-02-19 2019-01-08 Ono Pharmaceutical Co Compuesto inhibidor de cinasa del receptor de tropomiosina (trk).
WO2015072853A1 (en) * 2013-11-13 2015-05-21 Rjg Developments B.V. Treatment of herpes virus infection outbreaks
GB201321732D0 (en) 2013-12-09 2014-01-22 Ucb Pharma Sa Therapeutic agents
US9844551B2 (en) 2015-01-14 2017-12-19 Children's Hospital Medical Center Compositions and methods for treatment of fragile X syndrome
WO2016154031A1 (en) 2015-03-20 2016-09-29 Uwm Research Foundation, Inc. Gabaergic ligands and their uses
BR112018015386A2 (pt) 2016-01-27 2019-03-19 Universität Zürich uso de moduladores de receptor gabaa para tratamento de prurido

Also Published As

Publication number Publication date
KR20180118623A (ko) 2018-10-31
BR112018015386A2 (pt) 2019-03-19
KR102482200B1 (ko) 2022-12-27
CA3012791A1 (en) 2017-08-03
EP3407886A1 (en) 2018-12-05
RU2018128905A3 (enExample) 2020-03-24
US20210100814A1 (en) 2021-04-08
US20250268912A1 (en) 2025-08-28
US10786513B2 (en) 2020-09-29
US20190134057A1 (en) 2019-05-09
IL260775B (en) 2021-09-30
AU2017213154B2 (en) 2023-02-02
CA3222584A1 (en) 2017-08-03
US12433898B2 (en) 2025-10-07
MX2018009252A (es) 2019-01-21
SG11201806393QA (en) 2018-08-30
US11529359B2 (en) 2022-12-20
JP2022088620A (ja) 2022-06-14
WO2017129801A1 (en) 2017-08-03
JP2019507736A (ja) 2019-03-22
CN108697694A (zh) 2018-10-23
MX388862B (es) 2025-03-20
JP7115746B2 (ja) 2022-08-09
AU2017213154A1 (en) 2018-08-16
UA125463C2 (uk) 2022-03-16
CN108697694B (zh) 2022-12-09
CL2018002023A1 (es) 2019-02-01
RU2018128905A (ru) 2020-02-27

Similar Documents

Publication Publication Date Title
CA3012791A1 (en) Use of gabaa receptor modulators for treatment of itch
Ralvenius et al. Itch suppression in mice and dogs by modulation of spinal α2 and α3GABAA receptors
EP3022206B1 (en) Epha4 inhibitors as neuroprotective agents
US20220193053A1 (en) Cystic fibrosis transmembrane conductance regulator modulators for treating autosomal dominant polycystic kidney disease
WO2023089074A1 (en) Autophagy inducing compounds and uses thereof, in particular for a systemic treatment of diseases and conditions
EP3713644A1 (en) Compositions and methods for modulating hif-2& x391; to improve muscle generation and repair
Perez-Miller et al. Peptide and peptidomimetic inhibitors targeting the interaction of collapsin response mediator protein 2 with the N-type calcium channel for pain relief
CN111819190A (zh) 器官纤维化的预防和治疗
US9809820B2 (en) Treatment of hyperhidrosis
RU2781636C2 (ru) Применение модуляторов gabaa-рецептора для лечения зуда
EP3856156B1 (en) 5-ht7 antagonist for the treatment of dementia-associated tauopathies
HK1262708A1 (en) Use of gabaa receptor modulators for treatment of itch
EP3386510B1 (fr) Derives phosphores pour la prevention ou le traitement des myopathies et traumatismes musculaires
WO2023126076A1 (en) Medical use of an amide of y-hydroxybutyric acid in the treatment of fragile x syndrome
ES2794323B2 (es) Moxifloxacino para uso en el tratamiento de la atrofia muscular espinal
Fontelonga Development of Small Molecule Therapies Targeting Regeneration for the Treatment of Duchenne Muscular Dystrophy
WO2025042862A1 (en) Modulation of nuclear envelope protein expression for alleviation of nuclear pore complex injury cascades and tdp- 43 dysfunction in neurodegeneration
WO2014106720A1 (fr) Peptide pour son utilisation dans le traitement des neuronopathies motrices
WO2019165241A1 (en) Grp94 inhibitors to treat steroid-induced ocular hypertensions and glaucomas

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20220126

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - STANDARD

Year of fee payment: 8

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20241223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT

Effective date: 20241223

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20241223

MPN Maintenance fee for patent paid

Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 9TH ANNIV.) - STANDARD

Year of fee payment: 9

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20251223

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20251223